Table 2.
Basic characteristics and antibiotic resistance rate of the subjects.
|
Phenotype-guided therapy group
(n = 71) |
Genotype-guided therapy group
(n = 87) |
P | |
|---|---|---|---|
| Age | |||
| Mean ± SD (years) | 10.2 ± 2.5 | 9.7 ± 2.6 | 0.23 |
| Sex | |||
| Male | 67.6% (48/71) | 66.7% (58/87) | 0.90 |
| Female | 32.4% (23/71) | 33.3% (29/87) | |
| Chief compliant | |||
| Abdominal discomfort | 77.5% (55/71) | 79.3% (69/87) | 0.78 |
| Nausea or vomit | 19.7% (14/71) | 11.5% (10/87) | 0.15 |
| Other symptoms | 12.7% (9/71) | 14.9% (13/87) | 0.68 |
| Endoscopic findings | |||
| PUD | 18.3% (13/71) | 12.6% (11/87) | 0.34 |
| NUD | 81.7% (58/71) | 87.4% (76/87) | |
| Phenotype resistance | |||
| AMO | 2.8% (2/71) | 0 | 1.00 |
| MET | 31.0% (22/71) | 43.3% (13/30) | 0.23 |
PUD, peptic ulcer disease; NUD, non-ulcer disease; AMO, amoxicillin; MET, metronidazole.